Issues Related to Recent Dengue Vaccine Development

• Konishi Eiji

  Division of Infectious Diseases, Department of International Health, Kobe University Graduate School of Health Sciences Division of Vaccinology, Center for Infectious Diseases, Kobe University Graduate School of Medicine BIKEN Endowed Department of Dengue Vaccine Development, Faculty of Tropical Medicine, Mahidol University (Endowed from The Research Foundation for Microbial Diseases of Osaka University, Osaka, Japan to Research Institute for Microbial Diseases, Osaka University, Osaka, Japan)

抄録

Dengue fever (DF) and dengue hemorrhagic fever (DHF) are mosquito-transmitted diseases of global importance. Despite significant research efforts, no approved vaccines or antiviral drugs against these diseases are currently available. This brief article reviews the status of dengue vaccine development, with particular emphasis on the vaccine strategies in more advanced stages of evaluation; these include traditional attenuation, chimerization and engineered attenuation. Several aspects of these vaccine design strategies, including concerns about vaccine candidates inducing infection-enhancing antibodies, are also presented.

収録刊行物

• Tropical Medicine and Health

  Tropical Medicine and Health 39 (4SUPPLEMENT), S63-S71, 2011

  日本熱帯医学会

キーワード

• Dengue
• vaccine
• neutralizing antibody
• enhancing antibody

詳細情報

• CRID: 1390282680195955072
• NII論文ID: 10030727458
• NII書誌ID: AA11912846
• DOI: 10.2149/tmh.2011-s01
• ISSN: 13494147
• ISSN: 13488945
• Web Site: https://search.jamas.or.jp/link/ui/2012278241
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可